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pre-existing coronary lesion, yet act on newly formed
lesions—we simply don’t know.
As the power of the study was not sufﬁcient to render the
coronary end point statistically signiﬁcant, it is wise to state
that the currently available data do not allow to draw deﬁnite
conclusions regarding the efﬁcacy of statins on coronary
death in hemodialyzed patients. Absence of evidence is not
necessarily evidence of absence. We have to wait for the
outcome of the SHARP study to know the deﬁnite answer.7
The conclusion that statins are ineffective in dialyzed
patients is certainly not strictly proven and cannot be
answered conclusively today. Admittedly, it is possible that
coronary heart disease in terminal renal disease differs from
coronary heart disease in nonrenal patients and is resistant to
statin treatment as suggested by some previous observa-
tions8,9—but a Socratic attitude demands to admit that
currently we simply don’t know the answer.
We believe that at the current state of our ignorance it is
wise to continue with statins in patients who had been on
statins before dialysis, and, in view of their encouraging side-
effect proﬁle, to administer statins (admittedly without the
deﬁnite evidence) at least in dialysis patients with clinically
proven coronary heart disease.
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The Authors Reply: Ritz and Wanner1 provide insightful
remarks about the need to understand the limitations of
evidence from trials before applying the results in practice. In
our study, statin use in dialysis patients continued to rise
despite the results of the 4D study.2,3 We wish to emphasize
that the purpose of our study was not to applaud or criticize
physicians in their continued use of statins. We agree that
although the evidence from the 4D and AURORA studies
seem to suggest a lack of beneﬁt, the limitations of those trials
make the results less conclusive than they could be.4 Given
the resources needed to conduct randomized trials, it is vital
that they contribute to scientiﬁc knowledge without ambi-
guity. The availability of funds is a major challenge to
conducting trials of common cardiovascular medications.
Industries may be less interested in ﬁnancing these trials, as
dialysis patients represent a small proportion of the overall
market sales. Yet, our need for such evidence remains high, as
renal patients were frequently excluded from trials that
inﬂuenced the use of these medications in the general
population.5 The main purpose of our study was to explore
the translation of knowledge in renal practice. Our discussion
offers several explanations as to why physicians continued to
prescribe statins after the 4D study, which includes
uncertainty about the overall result. As Ritz and Wanner
point out, the SHARP trial will provide more information
about the effectiveness of statins in renal patients.6 We await
these results to guide the care of our patients.
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Very low blood pH is life
threatening
To the Editor: In the review ‘assessing acid–base disorders’,
Adrogue´ et al.1 have discussed the usefulness of three
approaches to assess acid–base disorders with the ﬁnal aim
‘to undertake appropriate intervention’ (p 1239). However,
they have omitted to discuss the importance of blood pH
per se (i.e., the concentration of hydrogen ions (Hþ ) in the
blood).
112 Kidney International (2010) 78, 110–114
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In their case 1 (p 1244), they report on ‘a 27-year-old
woman with type 1 diabetes mellitus y brought to the
emergency department with obtundation and severe
hyperpnea y’; her blood pH is 7.05, PaCO2 15mmHg
and standardized base excess 25mEq/l. The therapeutic
recommendation is a platonic ‘to reverse the organic
acidosis’.
According to Edge et al.,2 low blood pH (which implies a
high concentration of hydrogen ions Hþ ) is the cause of
decreased level of consciousness. The glycolytic enzyme
phosphofructokinase is pH dependent,3 as its activity
decreases with decreasing pH and thus, glucose utilization
in the brain cells is impaired. Therefore, the clinical
consequences of decreasing blood pH are drowsiness, stupor,
coma, and death in coma. In the reported obtunded woman,
the immediate cause of obtundation is her very low blood pH
of 7.05, regardless of which of the three discussed approaches
is the most useful. To avoid further deterioration of the
obtundation to frank coma (potentially lethal), it would be
necessary to administer alkalizing solutions intravenously as
soon as possible, to increase and normalize the low blood pH.
This has been life-saving also in desperate situations (e.g.,
Kamarzaman et al.4).
In their case 2 (p 1244), they report on ‘a 58-year-old man
with advanced chronic obstructive pulmonary disease and
congestive heart failurey. His medications includey diuretics’;
his blood pH is 7.41, PaCO2 58mmHg, standardized base excess
11mEq/l and Kþ 3.2mEq/l. The authors write on ‘metabolic
alkalosis (diuretic induced)’, and their recommendation is to
‘reduce the metabolic component and thus the blood pH by
administering potassium chloride’. Thus, they admit that the
cause of metabolic alkalosis is low blood potassium (3.2mEq/l).
When we assess acid–base disorders, it would be useful to say
simply that this patient is ‘hypokalemic alkalosis’, again regardless
of which of the discussed approaches is the most useful.
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The Authors Reply: We thank Dr Rosival for his letter.1
However important his points might be, they are unrelated to
the central focus of our paper.2 As the title of our paper
indicates, our aim was to evaluate the existing approaches to
assessing acid–base disorders.
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To the Editor: We read with interest the instructive case of
non-hepatitis virus-associated mixed essential cryoglobuline-
mia reported by Annear et al.1 The search for a situation
underlying, accompanying, or preceding a glomerulonephritis
can often be intriguing or puzzling, especially when it is
regarding a latent, quiescent, or multiphasic viral infection
presenting with a nonspeciﬁc clinical syndrome, such as in
the presented case. Are serological tests alone adequate for
the diagnosis of an acute infection and the connection of a
glomerulonephritis to the corresponding infection? There are
infections, such as parvovirus infections, wherein even the
immunoglobulin M levels are maintained high for several
months after the acute infection.2,3 This ﬁnding restricts their
diagnostic value and, therefore, one should be cautious in
their interpretation for the diagnosis of the acute phase of
infections. In this particular case, the diagnosis of acute
parvovirus infection was made on the basis of the positive
serological test. In such cases, the use of polymerase chain
reaction test for the detection of viral nucleic acid, although
lacks validation for many infections, can provide more solid
answers regarding the diagnosis of an acute infection.
Although one cannot rule out the possibility that parvovirus
infection might have triggered the production of cryoglobu-
lins, the presumed association of the cryoglobulinemic
glomerulonephritis with parvovirus B19 infection needs a
more careful dissection, as long as no etiological connection
between the two entities has been documented in this case;
moreover, unlike hepatitis C virus-related cryoglobulinemia,
cryoglobulin was not found to be directed against parvovirus.
From a clinical standpoint, this is not surprising, as long as it
is known that chronic rather than acute infections usually
lead to clinically signiﬁcant cryoglobulinemia. Furthermore,
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